U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: Description was created based on several sources, including: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=317cc880-73fe-4561-897e-41489108b3ba http://www.drugbank.ca/drugs/DB00803 http://www.rxlist.com/coly-mycin-s-otic-drug.htm https://www.niaid.nih.gov/topics/antimicrobialResistance/Pages/colistin.aspx

Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. It is a cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C). Colistin was first isolated in Japan in 1949 from a flask of fermenting Bacillus polymyxa var. colistinus and became available for clinical use in 1959. The following local adverse events have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, etc. Healthcare providers had largely stopped using colistin in the 1970s because of its toxicity. However, with antibacterial resistance on the rise, colistin is increasingly being used today to treat severe, multidrug-resistant Gram-negative bacterial infections, particularly among intensive care-based patients. The problem with re-introducing an older drug, such as colistin, though, is that techniques for evaluating new drugs have evolved since the 1950s, and therefore, little is known about the dose needed to effectively fight infection while limiting the potential emergence of antimicrobial resistance and reducing potentially toxic side effects. More data are needed to guide optimal use of these older medications. An international team of NIAID-funded researchers is making progress in obtaining better dosing information about colistin and how best to use the antibiotic to treat Gram-negative bacterial infections. Resistance to colistin is rare. The first colistin-resistance gene that is carried in a plasmid and can be transferred between bacterial strains was described in 2016. This plasmid-borne mcr-1 gene has since been isolated in China, Europeand the United States.

Originator

Curator's Comment: Colistin was first discovered by Koyama et al. in 1949.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Bacterial outer membrane
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
COLY-MYCIN S

Approved Use

Cortisporin®-TC Otic Suspension is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics.

Launch Date

1962
Curative
COLY-MYCIN S

Approved Use

Cortisporin®-TC Otic Suspension is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics.

Launch Date

1962
PubMed

PubMed

TitleDatePubMed
Antibacterial agents in renal failure.
1971 May 29
Myopathy caused by polymyxin E: functional disorder of the cell membrane.
1974 Dec
Therapeutic efficacy of tobramycin--a clinical and laboratory evaluation.
1975 Dec
Further studies on effects of irrigation solutions on rat bladders.
1976 Dec
Deafness and biochemical imbalance after burns treatment with topical antibiotics in young children. Report of 6 cases.
1978 Apr
Emerging treatments in cystic fibrosis.
2009 Oct 1
Synergy of the antibiotic colistin with echinocandin antifungals in Candida species.
2013 Jun
Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers.
2014 Feb
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Therapy with Coly-Mycin S (Colistin-containing suspension) should be limited to 10 days.
For adults, 5 drops of the suspension into the affected ear 3 or 4 times daily. For pediatric patients, 4 drops are suggested.
Route of Administration: Otic (auricular)
In Vitro Use Guide
Lethal concentrations of colistin of 50 and 100 µg/ml caused about 90 and 99% cell death, respectively.
Substance Class Mixture
Created
by admin
on Fri Dec 15 15:58:55 GMT 2023
Edited
by admin
on Fri Dec 15 15:58:55 GMT 2023
Record UNII
Z67X93HJG1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
COLISTIN
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
Colistin [WHO-DD]
Common Name English
SOGECOLI
Brand Name English
colistin [INN]
Common Name English
COLISTIN [MI]
Common Name English
POLYMYXIN E
Common Name English
COLISTIN [VANDF]
Common Name English
COLISTIN [HSDB]
Common Name English
Classification Tree Code System Code
WHO-ATC J01XB01
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
WHO-VATC QA07AA10
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
WHO-VATC QJ01XB01
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
NCI_THESAURUS C78160
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
WHO-VATC QA07AA98
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
WHO-ATC A07AA10
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
WHO-VATC QG51AG07
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
WHO-VATC QJ51XB01
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
Code System Code Type Description
CHEBI
37943
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
PRIMARY
INN
916
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
PRIMARY
FDA UNII
Z67X93HJG1
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
PRIMARY
CAS
1066-17-7
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
PRIMARY
NCI_THESAURUS
C65350
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
PRIMARY
DRUG CENTRAL
4425
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
PRIMARY
MESH
D003091
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
PRIMARY
WIKIPEDIA
COLISTIN
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
PRIMARY
RXCUI
2709
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
PRIMARY RxNorm
EVMPD
SUB01429MIG
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
PRIMARY
ECHA (EC/EINECS)
213-907-3
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
PRIMARY
DRUG BANK
DB00803
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
PRIMARY
ChEMBL
CHEMBL2221249
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
PRIMARY
HSDB
3045
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
PRIMARY
MERCK INDEX
m3733
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID1040663
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
PRIMARY
DAILYMED
Z67X93HJG1
Created by admin on Fri Dec 15 15:58:55 GMT 2023 , Edited by admin on Fri Dec 15 15:58:55 GMT 2023
PRIMARY
All of the following components must be present:
Definition References